Search Results
Jun 30, 2026, 07:05 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
improvement.Treatment with SKY-0515 resulted in dose-dependent reductions in mutant huntingtin (mHTT) protein in blood of up to 69% as well as reductions in PMS1 mRNA of up to 26%. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Skyhawk Therapeutics Releases Twelve-Month cUHDRS Subcomponent Results from its Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease
improvement.Treatment with SKY-0515 resulted in dose-dependent reductions in mutant huntingtin (mHTT) protein in blood of up to 69% as well as reductions in PMS1 mRNA of up to 26%. Mutant huntingtin is the primary protein responsible for HD pathology, while PMS1 is a key driver of somatic CAG repeat expansion associated
More news about: Skyhawk Therapeutics
Jun 30, 2026, 07:00 ET Samsung Biologics Releases 2026 ESG Report, Highlighting Progress in Sustainable Operations and Responsible Growth
cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics.By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced
More news about: Samsung Biologics
Jun 30, 2026, 05:37 ET METiS TechBio and Boulevard Bio Enter Global License Agreement for Trispecific T-cell Engager
wet lab + agent-based intelligence" innovation framework, powering four core solution engines: AiLNP (AI-driven lipid nanoparticle design), AiRNA (AI mRNA sequence design), AiProtein (AI protein and antibody design), and AiTEM (AI small molecule formulation design).NanoForge enables an end-to-end
More news about: METiS TechBio
Jun 29, 2026, 13:57 ET Study Reveals How Leukemia Cells Enter and Damage Lungs
used single-cell transcriptomics, a technique that measures the activity of genes in individual cells. By capturing the active genetic signals (e.g., mRNA sequences) of thousands of individual cells simultaneously, it reveals cellular diversity and identifies rare cell types. They also used spatial transcriptomics
More news about: NYU Langone Health System
Jun 26, 2026, 09:01 ET Nippon Shinyaku and Elixirgen Therapeutics Enter Option Agreement for Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
supporting our community and the necessary scientific exploration needed to combat rare disease."EXG-7001 is an investigational, locally administered, mRNA based therapeutic drug that expresses full-length human dystrophin protein. Regardless of genetic mutation, it is intended to suppress local muscle
More news about: NS Pharma, Inc.
Jun 25, 2026, 10:31 ET Huntington's Disease Market Poised for Significant Growth at a CAGR of 14% During the Forecast Period (2026-2036) Amid Advancements in Disease-Modifying Therapies | DelveInsight
production through a distinct mechanism of action. The therapy promotes the inclusion of a pseudoexon containing a premature stop codon within HTT mRNA, leading to mRNA degradation and, consequently, decreased HTT protein expression.Prilenia Therapeutics' Pridopidine is a first-in-class, highly
More news about: DelveInsight Business Research, LLP
Jun 25, 2026, 08:30 ET Servier Announces First Patient Enrolled in Phase Ib/II Study for the Treatment of a Rare Pediatric Epilepsy Syndrome in the U.S.
trial is an investigational ASO, which is an innovative modality designed to target the genetic cause of KCNT1-DEE. It acts by degrading KCNT1 mRNA with the aim of modifying the disease in patients and has been shown to be well-tolerated in pre-clinical studies."In many children with a KCNT1
More news about: Servier Pharmaceuticals
Jun 24, 2026, 08:30 ET Improve Blood Assay Analyte Preservation & Recovery with Advanced Materials, Upcoming Webinar Hosted by Xtalks
present data from a multi-donor study comparing dry-state microsampling with conventional liquid blood collection. Using qPCR analysis of isolated mRNA, researchers observed comparable relative expression of biomarkers associated with T cells (CD3+, CD4+, CD8+), B cells and natural killer cells between
More news about: Xtalks
Jun 23, 2026, 13:26 ET Das Gesundheitsministerium und Sanofi gehen Partnerschaft ein, um Innovationen im Bereich der Impfstoffe voranzutreiben
Impfstoffinnovationszentrums in Abu Dhabi zu prüfen. Die Zusammenarbeit würde die Kompetenzen in den Bereichen KI-gestützte Impfstoffforschung, mRNA-Forschung, klinische Entwicklung und Herstellung stärken und die regionale sowie globale Vorsorge für künftige Herausforderungen im Bereich der öffentlichen
More news about: The Department of Health - Abu Dhabi
Jun 22, 2026, 19:29 ET DoH and Sanofi Partner to Advance Vaccine Innovation
explore the development of a Vaccine Innovation Centre in Abu Dhabi. The collaboration would strengthen capabilities across AI-enabled vaccine discovery, mRNA research, clinical development and manufacturing, and support regional and global preparedness for future public health challenges.
More news about: The Department of Health - Abu Dhabi
Jun 22, 2026, 19:20 ET DoH and Sanofi Partner to Advance Vaccine Innovation
explore the development of a Vaccine Innovation Centre in Abu Dhabi. The collaboration would strengthen capabilities across AI-enabled vaccine discovery, mRNA research, clinical development and manufacturing, and support regional and global preparedness for future public health challenges.
More news about: The Department of Health - Abu Dhabi
Jun 22, 2026, 07:00 ET Taiwan Biotech Delegation Heads to BIO 2026 to Advance Global Partnerships and Innovation
Bio-ManufacturingA pure-play CRDMO providing GMP solutions for mRNA, cell therapy, viral vectors & complex biologics.
More news about: BPIPO
Jun 19, 2026, 18:21 ET New 5W AI Visibility Index: Pharma Spends Billions on DTC Ads. The AI Engines Talk About Eli Lilly and Novo Nordisk Anyway
— Immunology & inflammation — 5.0%07. AstraZeneca — Oncology & specialty — 4.0%08. Moderna — Vaccines & mRNA — 3.5%09. Amgen — Biologics & specialty — 3.0%10. Novartis — Specialty & gene therapy — 2.6%11.
More news about: 5W Public Relations
Jun 19, 2026, 07:30 ET Replicate Bioscience Awarded Grant to Advance srRNA Vaccine Candidates for Tuberculosis
existing mRNA approaches, with potential improvements in bioactivity, induction of more potent immune responses, and improved therapeutic index. RBI-4000, the company's clinical-stage srRNA rabies vaccine, has demonstrated protective levels of immunity at doses lower than any other reported mRNA or srRNA
More news about: Replicate Bioscience
Jun 17, 2026, 08:00 ET Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
FHCC minicircle plasmids have shown increases of 100,000x compared to standard plasmid technologies. Our first initiatives focus on the development of mRNA related assembly proteins – the Tobacco Etch Virus (TEV) Protease and the T7 RNA Polymerase.Our objective is to establish a foundation for the
More news about: Azitra, Inc.
Jun 17, 2026, 01:39 ET Ligufalimab (CD47)-Based Combination Achieves Deep Responses and Survival Benefit in Frontline AML: Phase II Results Presented in Oral Session at EHA 2026
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Jun 16, 2026, 19:00 ET Waters, GLP-1 특성화 분석을 최대 3배, LNP 성분 분석을 최대 2배 더 빠르게 수행할 수 있는 업계 최초의 역상 바이오분리 컬럼 출시
GLP-1 수용체 작용제와 생체 내 CAR-T와 같은 차세대 mRNA 기반 치료제에서는 불순물 분리가 어려울 경우 제품 출시가 지연될 수 있으며 규제기관의 신뢰도가 저하될 수 있으며, 궁극적으로 환자 안전에도 영향을 미칠 수 있다. 기존의 RP 컬럼은 미량 불순물이나 밀접하게 관련된 불순물을 충분히 분리하지 못하는 경우가 많아, 분석
More news about: Waters Corporation
Jun 16, 2026, 11:04 ET Pew Supports 10 Leading Latin American Scientists
Ph.D.Boyce Thompson InstituteLaura Gonzalez Garcia, Ph.D., will explore the unique differences in how an RNA modification influences mRNA stability and turnover in plants and humans.Founded in 1948, The Pew Charitable Trusts uses data to make a difference. Pew addresses the challenges
More news about: The Pew Charitable Trusts
Jun 16, 2026, 11:04 ET Pew apoia 10 cientistas pioneiros da América Latina
InstituteLaura Gonzalez Garcia, Ph.D., vai explorar as diferenças únicas na forma como a modificação de RNA influencia a estabilidade e a rotatividade do mRNA em plantas e humanos.Fundada em 1948, a Pew Charitable Trusts usa dados para fazer a diferença. A Pew enfrenta os desafios de um mundo em
More news about: The Pew Charitable Trusts
Jun 16, 2026, 10:08 ET Inflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity®
under development (such as PCR tests).TriVerity® takes a fundamentally different approach by measuring the body's immune response through host mRNA, providing clinicians with three actionable insights from a single blood sample: likelihood of bacterial infection, likelihood of viral infection, and
More news about: Inflammatix
Jun 16, 2026, 07:00 ET DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster
More news about: Dimerix Limited
Jun 15, 2026, 02:52 ET Akeso's Next-Generation HER3 ADC AK138D1 Combined with Ivonescimab: First Patient Enrolled in Phase Ib/II Breast Cancer Study, Advancing the IO2.0 + ADC2.0 Strategy
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed by world-class GMP manufacturing facilities and a highly efficient, integrated
More news about: Akeso, Inc.
Jun 12, 2026, 00:52 ET ウォーターズ、業界初となる逆相バイオセパレーションカラムを発売 -- GLP-1 特性解析を最大 3 倍、LNP 成分分析を最大 2 倍高速化
GLP-1 受容体作動薬や、in vivo CAR-T をはじめとする新しい mRNA ベースの治療法では、不純物の分離が困難であることが市場投入の遅延を招き、規制当局からの信頼を損ない、さらには患者の安全性に影響を及ぼす可能性があります。従来の RP カラムでは、低濃度の不純物や類似した不純物を十分に分離できない場合があり、その結果、分析時間の長期化や、検出感度を低下させる移動相添加剤の使用、さらにはメソッドの再開発を繰り返す必要が生じることが少なくありませんでした。BioResolve
More news about: Waters Corporation
Jun 11, 2026, 21:57 ET Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms. Supported by a global-standard GMP manufacturing infrastructure and a highly efficient,
More news about: Akeso, Inc.